VALNEVA SE SP.ADS/2 (F:AYJ0) — Market Cap & Net Worth
Market Cap & Net Worth: VALNEVA SE SP.ADS/2 (AYJ0)
VALNEVA SE SP.ADS/2 (F:AYJ0) has a market capitalization of $438.08 Million (€374.72 Million) as of September 20, 2026. Listed on the F stock exchange, this Germany-based company holds position #13058 globally and #1373 in its home market, demonstrating a -2.65% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying VALNEVA SE SP.ADS/2's stock price €5.50 by its total outstanding shares 94823458 (94.82 Million). Also see VALNEVA SE SP.ADS/2 balance sheet assets for a full breakdown of the balance sheet.
VALNEVA SE SP.ADS/2 Market Cap History: 2021 to 2026
VALNEVA SE SP.ADS/2's market capitalization history from 2021 to 2026. Data shows change from $5.48 Billion to $609.72 Million (-24.23% CAGR). Also see AYJ0 cash flow metrics for how efficiently the company converts equity into cash flow.
VALNEVA SE SP.ADS/2 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how VALNEVA SE SP.ADS/2's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check AYJ0 live share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
4.63x
VALNEVA SE SP.ADS/2's market cap is 4.63 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $5.48 Billion | $348.08 Million | -$73.42 Million | 15.73x | N/A |
| 2022 | $1.37 Billion | $361.30 Million | -$143.28 Million | 3.79x | N/A |
| 2023 | $1.01 Billion | $153.71 Million | -$101.43 Million | 6.56x | N/A |
| 2024 | $487.78 Million | $169.58 Million | -$12.25 Million | 2.88x | N/A |
| 2025 | $809.27 Million | $174.66 Million | -$115.19 Million | 4.63x | N/A |
Competitor Companies of AYJ0 by Market Capitalization
Companies near VALNEVA SE SP.ADS/2 in the global market cap rankings as of September 20, 2026. Review AYJ0 tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to VALNEVA SE SP.ADS/2 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
VALNEVA SE SP.ADS/2 Historical Marketcap From 2021 to 2026
Between 2021 and today, VALNEVA SE SP.ADS/2's market cap moved from $5.48 Billion to $ 609.72 Million, with a yearly change of -24.23%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €609.72 Million | -24.66% |
| 2025 | €809.27 Million | +65.91% |
| 2024 | €487.78 Million | -51.65% |
| 2023 | €1.01 Billion | -26.32% |
| 2022 | €1.37 Billion | -75.00% |
| 2021 | €5.48 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of VALNEVA SE SP.ADS/2 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $438.08 Million USD |
| MoneyControl | $438.08 Million USD |
| MarketWatch | $438.08 Million USD |
| marketcap.company | $438.08 Million USD |
| Reuters | $438.08 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About VALNEVA SE SP.ADS/2
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile t… Read more